市场调查报告书
商品编码
1463622
南美洲和中美洲生物製药冻干服务市场预测至 2028 年 - 区域分析 - 按服务类型和最终用户South & Central America Lyophilization Services for Biopharmaceuticals Market Forecast to 2028 - Regional Analysis - by Service Type and End-User |
2023年南美洲和中美洲生物製药冻干服务市场价值为7002万美元,预计到2028年将达到1.0437亿美元;预计 2023 年至 2028 年CAGR为 8.3%。
合约製造和冷冻干燥服务的快速成长推动了南美洲和中美洲生物製药市场的冷冻干燥服务
生物製药市场在全球持续扩张,这可能成为製药业的主要成长动力。随着更多治疗性生物製剂获得批准,生物製药肠外生产最近有所扩大。生物技术公司从合约製造组织 (CMO) 外包,以满足其填充和加工需求并降低微生物污染的风险。生物製药公司依赖合约製造组织 (CMO) 来提供所需的产能和能力;在某些情况下,CMO 提供公司大量的产品。
建立内部冻干能力和操作需要专门的设备和专业知识,这是昂贵且耗时的。然而,外包成本更低,并且提高了製造流程的效率。此外,它还允许生物技术公司将资源重新分配到其他领域。因此,药物开发商和生物製药公司将此类业务外包给 CMO,以节省整体生产和产量成本。几年前,CMO 产业是一个利基服务市场,为生物技术公司提供额外的製造能力或特定服务。现在,许多生技公司外包各种服务,从早期药物开发到商业规模製造。随着生技产业从大规模生产转向小众、标靶治疗(个人化医疗),对灵活营运能力、生产规模和多产品营运的需求不断上升。由于所有这些因素,对 CMO 的倾向正在增长。因此,生物製药 CMO 的能力和可用性不断提高,推动了南美洲和中美洲冻干服务的生物製药市场成长。
南美洲和中美洲生物製药冻干服务市场概述
南美洲和中美洲地区包括巴西、阿根廷以及南美洲和中美洲的其他地区。预计巴西将在该地区占据主要市场份额。由于製药和生物製药行业的巨大研发投资,市场可能有良好的成长机会。此外,与外国当局和组织的合作可能需要这些国家的冻干服务。
南美洲和中美洲生物製药冻干服务市场收入及 2028 年预测(百万美元)
南美洲和中美洲生物製药冻干服务市场细分
南美洲和中美洲生物製药市场的冷冻干燥服务按服务类型、最终用户和国家进行细分。
根据服务类型,南美洲和中美洲生物製药市场冻干服务分为冷冻干燥循环开发、临床製造、商业製造和冷冻干燥分析服务。 2023 年,商业製造领域占据最大的市场份额。
根据最终用户,南美洲和中美洲生物製药市场冻干服务分为製药和生技公司、研究机构等。 2023 年,製药和生技公司细分市场占据最大的市场。
根据国家/地区,南美洲和中美洲生物製药市场的冷冻干燥服务分为巴西、阿根廷以及南美洲和中美洲其他地区。 2023 年,巴西在南美洲和中美洲生物製药冻干服务市场份额中占据主导地位。
ABB、Azbil Corporation、Curia Global Inc、Grifols SA、Jubilant HollisterStier LLC. 和 OPTIMA 是南美洲和中美洲生物製药市场冻干服务领域的一些领先公司。
The South & Central America lyophilization services for biopharmaceuticals market was valued at US$ 70.02 million in 2023 and is expected to reach US$ 104.37 million by 2028; it is estimated to grow at a CAGR of 8.3% from 2023 to 2028.
Rapid Growth in Contract Manufacturing and Lyophilization Services Fuels the South & Central America Lyophilization Services for Biopharmaceuticals Market
The biopharmaceuticals market continues to expand across the world, which can be the primary growth driver for the pharmaceutical industry. Biopharmaceutical parenteral manufacturing has expanded recently as more therapeutic biologics have been approved. Biotechnology companies outsource from contract manufacturing organizations (CMOs) to meet their fill-and-finish needs and reduce the risk of microbial contamination. Biopharma companies are dependent on contract manufacturing organizations (CMOs) to provide capacity and capabilities as needed; in some cases, CMOs provide a great deal of a company's production.
Setting up in-house lyophilization capabilities and operations requires specialized equipment and expertise, which is an expensive and time-consuming. However, outsourcing is cheaper and increases the efficiency of manufacturing processes. Additionally, it allows biotechnology companies to redirect resources to other areas. Thus, drug developers and biopharmaceutical companies outsource such operations to CMOs to save overall production and yield cost. A few years ago, the CMO industry was a niche service market, offering additional manufacturing capacity or specific services to biotechnology companies. Now, many biotechnology companies outsource various services, from early-stage drug development to commercial-scale manufacturing. As the biotechnology industry is shifting from large-scale production to niche and targeted therapies (personalized medicine), the demand for flexible operational capabilities, production scales, and multiple-product operations is rising. Owing to all these factors, the inclination toward CMOs is growing. Thus, the rising capability and availability of biopharma CMOs fuel the South & Central America lyophilization service for biopharmaceuticals market growth.
South & Central America Lyophilization Services for Biopharmaceuticals Market Overview
South and Central America region consist of Brazil, Argentina, and the Rest of the South and Central America. Brazil is expected to have a major market share in this region. The market is likely to have good growth opportunities owing to the huge investment for research and development in the pharmaceutical and biopharmaceutical industry. In addition, the collaboration with foreign authorities and organizations is likely to demand the lyophilization services in the countries.
South & Central America Lyophilization Services for Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Mn)
South & Central America Lyophilization Services for Biopharmaceuticals Market Segmentation
The South & Central America lyophilization services for biopharmaceuticals market is segmented service type, end user, and country.
Based on service type, the South & Central America lyophilization services for biopharmaceuticals market is segmented into lyophilization cycle development, clinical manufacturing, commercial manufacturing, and freeze drying analytical services. The commercial manufacturing segment held the largest market share in 2023.
Based on end-user, the South & Central America lyophilization services for biopharmaceuticals market is segmented into pharmaceutical & biotechnology companies, research institutes, and other. The pharmaceutical & biotechnology companies segment held the largest market share in 2023.
Based on country, the South & Central America lyophilization services for biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America lyophilization services for biopharmaceuticals market share in 2023.
ABB, Azbil Corporation, Curia Global Inc, Grifols S.A., Jubilant HollisterStier LLC., and OPTIMA are some of the leading companies operating in the South & Central America lyophilization services for biopharmaceuticals market.